SEC 13F Intelligence

Managers / Q1 2026

Kalehua Capital Management LLC

CIK 0002106181 · 3819 MAPLE AVENUE, DALLAS, TX, 75219 · 214-225-0846

Reported Value
$260M
Q1 2026
Positions
50
includes revealed positions
Filings on Record
3
2019–present window
Filed
May 15, 2026
original filing

Summary

Kalehua Capital Management LLC reported $260M in U.S.-listed holdings across 50 positions for Q1 2026.

Its largest position, XFOR, represents 5.9% of the portfolio.

Compared with Q4 2025, the fund opened 9 new positions and exited 3.

Portfolio Metrics

Turnover
+4.2%
vs prior filed quarter
Top-10 Concentration
+45.5%
share of reported value
Largest Position
+5.9%
X4 Pharmaceuticals
New / Exited
9 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’25: $101MQ4 ’25Q1 ’26: $260MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 74.0%ETP: 15.1%Other: 7.5%ADR: 3.5%
  • Common Stock · 74.0% · $192M
  • ETP · 15.1% · $39M
  • Other · 7.5% · $19M
  • ADR · 3.5% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MANEVERADERMICS INCREVEALEDNEW+248.6K248.6K+$16M$16M
ACRSACLARIS THERAPEUTICS INCREVEALEDNEW+3.17M3.17M+$12M$12M
Uniqure NVREVEALEDNEW+502.8K502.8K+$8M$8M
DMRADamora Therapeutics IncREVEALEDNEW+278.0K278.0K+$7M$7M
GOSSGossamer Bio IncREVEALEDNEW+17.71M17.71M+$6M$6M
PEPGPepGen IncREVEALEDNEW+1.73M1.73M+$3M$3M
TILInstil Bio IncREVEALEDNEW+322.9K322.9K+$3M$3M
KRROKORRO BIO INCREVEALEDNEW+109.4K109.4K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026REVEALED

26 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1XFORX4 Pharmaceuticals IncREVEALEDhistory →COM NEW11.83%$31M7.45M
2Alpha Architect 1-3 Month Box ETFREVEALEDALPHA ARCH 1-310.60%$28M236.8K
3SRZNSurrozen IncREVEALEDhistory →COM NEW8.63%$22M770.4K
4RLAYRelay Therapeutics IncREVEALEDhistory →COM6.90%$18M1.80M
5SIONSionna Therapeutics IncREVEALEDhistory →COM6.08%$16M394.1K
6MANEVeradermics IncREVEALEDhistory →COMMON STOCK6.04%$16M248.6K
7ACRSACLARIS THERAPEUTICS INCREVEALEDhistory →COM4.57%$12M3.17M
8ORKAOruka Therapeutics IncREVEALEDhistory →COM4.47%$12M237.0K
9EA SERIES TRUSTREVEALEDALPHA ARCH 1-34.47%$12M99.9K
10Pharvaris NVREVEALEDCOM4.32%$11M397.5K
11IKTInhibikase Therapeutics IncREVEALEDhistory →COM NEW4.20%$11M6.49M
12SEPNSepterna IncREVEALEDhistory →COM3.60%$9M389.1K
13CMPSCompass Pathways PLCREVEALEDhistory →SPONSORED ADS3.49%$9M1.64M
14Uniqure NVREVEALEDSHS3.16%$8M502.8K
15LONALeonaBio IncREVEALEDhistory →COM3.11%$8M787.4K
16DMRADamora Therapeutics IncREVEALEDhistory →COM NEW2.77%$7M278.0K
17MLTXMoonLake ImmunotherapeuticsREVEALEDhistory →CLASS A ORD2.52%$7M351.5K
18GOSSGossamer Bio IncREVEALEDhistory →COM2.24%$6M17.71M
19TYRATyra Biosciences IncREVEALEDhistory →COM2.19%$6M148.9K
20PEPGPepGen IncREVEALEDhistory →COM1.18%$3M1.73M
21TNYATenaya Therapeutics IncREVEALEDhistory →COM1.07%$3M4.00M
22TILInstil Bio IncREVEALEDhistory →COM NEW1.02%$3M322.9K
23KLRSKalaris Therapeutics IncREVEALEDCOM0.60%$2M271.2K
24KRROKORRO BIO INCREVEALEDCOM0.48%$1M109.4K
25DMACDiaMedica Therapeutics IncREVEALEDCOM NEW0.33%$846,088125.0K
26LOOPLONGEVERON INCREVEALEDCOM0.14%$361,441347.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026REVEALED$260M50May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$101M19Feb 13, 202613F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.